Lemon Flavonoid Blend Eriomin May Serve as Adjunct Therapy to Metformin in High Blood Sugar: Study

A lemon flavonoid blend marketed by Ingredients by Nature as Eriomin was found to enhance the effects of metformin in a clinical study on early management of hyperglycemia compared to metformin taken alongside a placebo in a human clinical study. The findings were published in Frontiers in Nutrition.

The 26-week double-blind, randomized, placebo-controlled, crossover study involved 71 prediabetic men and women between the ages of 18 and 65. Groups either received 250 mg of Eriomin alongside metformin, or a placebo with metformin. Compared to the placebo group, supplementation with the flavonoid blend, which is mainly composed of eriocitrin, appeared to enhance glucose metabolism, including a 5% reduction in 2-h OGTT glucose and preservation of active GLP-1 levels. In contrast, the group receiving a placebo saw a decline in GLP-1 levels and increased insulin resistance.

The Eriomin group also experienced an average 12% reduction in TNF-a, a 7.5% increase in plasma antioxidant capacity, and modest but significant decreases in body weight, fat mass, and BMI. Further, systolic blood pressure was reduced by 4%, potentially associated with antioxidant status and higher dietary potassium intake.

“We are thrilled with the outcome of this clinical research. Frequently, there are concerns that medications or supplements might adversely impact each other when taken in conjunction. This study may offer assurances that no adverse interactions were seen when taken by otherwise healthy but metabolically sensitive individuals, said Rob Brewster, president at Ingredients By Nature. “This is the fourth published human clinical study conducted on Eriomin, further backing its significant positive effects in supporting glycemic control, metabolic markers, GLP-1 levels, and antioxidant status.”